Futures point higher; AMD reports; Novo to cut costs - what’s moving markets
Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma (OTC:PMMAF) Biotechnology, INC. (NASDAQ:PBYI), a profitable biotech company with a market cap of $175 million and strong financial health according to InvestingPro, sold a total of 7817 shares of common stock on July 8th and 9th, 2025. The sales were executed in two transactions at prices ranging from $3.533 to $3.535, netting a total of $27624.
On July 8, Hunt sold 4374 shares. Following this transaction, on July 9, Hunt sold 3443 shares. Following these transactions, Hunt directly owns 164894 shares of Puma Biotechnology. The company trades at an attractive P/E ratio of 4.6x and has demonstrated strong profitability with a 72% gross margin.
These transactions were executed pursuant to a pre-arranged trading plan under Rule 10b5-1(c), which was adopted on December 14, 2020. InvestingPro analysis reveals 6 additional key insights about PBYI’s financial health and growth prospects, available exclusively to subscribers.
In other recent news, Puma Biotechnology reported its financial outcomes for the first quarter of 2025, revealing earnings per share of $0.06, which did not meet market expectations. The company’s revenue was $46 million, falling short of the forecasted $47.5 million. Puma Biotechnology continues to anticipate full-year NERLYNX product revenue between $192 million and $198 million. In addition, the company is projecting second-quarter 2025 NERLYNX product revenue to range from $48 million to $50 million. The company also announced the departure of Chief Commercial Officer Jeff Ludwig, effective immediately, with no plans to appoint a replacement. Instead, existing sales and marketing personnel will absorb Ludwig’s duties. This move may indicate an operational restructuring or a shift in commercial strategy for Puma Biotechnology. These developments reflect the company’s ongoing efforts to navigate financial challenges and strategic changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.